Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 2/20 | 0.55 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429746 | 1.00 | GABBR2 (0.55) | GABBR2GABBR1TAAR1HTR2ALMNA | |
| SCHEMBL2344157 | 1.00 | GABBR2 (0.55) | GABBR2GABBR1TAAR1HTR2ALMNA | |
| Hydrochloric Acid SCHEMBL2346631 | 0.98 | GABBR2 (0.53) | GABBR2GABBR1TAAR1HTR2ALMNA | |
| SCHEMBL17906514 | 0.87 | CHRNB2 (0.59) | GABBR2GABBR1TAAR1HTR2ACHRNB2 | |
| Methylamine SCHEMBL27931105 | 0.85 | LMNA (0.52) | GABBR2GABBR1TAAR1HTR2ALMNA | |
| SCHEMBL1539105 | 0.85 | TAAR1 (0.65) | GABBR2GABBR1TAAR1HTR2ACHRNB2 | |
| SCHEMBL169508 | 0.85 | LMNA (0.56) | TAAR1HTR2ALMNAHRH1CCR5 | |
| Hydrochloric Acid SCHEMBL10676327 | 0.82 | TAAR1 (0.62) | GABBR2GABBR1TAAR1HTR2ACHRNB2 | |
| Ammonia Solution, Strong SCHEMBL1640901 | 0.82 | LMNA (0.54) | TAAR1HTR2ALMNAHRH1CCR5 | |
| SCHEMBL19734403 | 0.82 | GABBR2 (0.52) | GABBR2GABBR1TAAR1HTR2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018152494-A1 | PASSIVATION OF DEFECTS IN PEROVSKITE MATERIALS FOR IMPROVED SOLAR CELL EFFICIENCY AND STABILITY | NUTECH VENTURES (US) | 2018-08-23 | — | — | WO | claimed |
| WO-2022261243-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| EP-3193604-B1 | SUBSTITUTED N-(PYRROLIDIN-3-YL)ISOXAZOLE-3-CARBOXAMIDE COMPOUNDS | EPIZYME INC (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| EP-3013812-B1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10125226-B2 | Scale-up process of bifunctionalized triblock copolymers with secondary and tertiary amines, with application in dewatering and desalting of heavy crude oils | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2018-11-13 | — | — | US | disclosed |
| US-9944589-B2 | Cycloproplyamine derivatives useful as inhibitors of histone demethylases KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2018-04-17 | — | — | US | disclosed |
| US-20170362217-A1 | Substituted Piperidine Compounds | Epizyme, Inc. (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2009105824-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MIMETICA PTY LTD (AU) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009105824-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MIMETICA PTY LTD (AU) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009105823-A1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | MIMETICA PTY LTD (AU) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009105823-A1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | MIMETICA PTY LTD (AU) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009105825-A1 | 3-SUBSTITUTED-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | MIMETICA PTY LTD (AU) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009105825-A1 | 3-SUBSTITUTED-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | MIMETICA PTY LTD (AU) | 2009-09-03 | — | — | WO | disclosed |
| US-20090221558-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | Marp Therapeutics Pty Ltd (AU) | 2009-09-03 | — | — | US | disclosed |
| US-20090221558-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | Marp Therapeutics Pty Ltd (AU) | 2009-09-03 | — | — | US | disclosed |
| US-20090221558-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | Marp Therapeutics Pty Ltd (AU) | 2009-09-03 | — | — | US | disclosed |
| WO-2008079759-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362217-A1 | Substituted Piperidine Compounds | SMYD3, SMYD2, SNRPD3 | GABBR2 2012/4885GABBR1 2638/4885TAAR1 3266/4885 |
| US-20090221558-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MC5R, MC1R, MC3R | GABBR2 678/4885GABBR1 749/4885TAAR1 334/4885 |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | GABBR2 2825/4885GABBR1 3404/4885TAAR1 4297/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | GABBR2 1681/4885GABBR1 2442/4885TAAR1 4421/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | GABBR2 1088/4885GABBR1 1945/4885TAAR1 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.